Jazz hands Tobias CMO role
This article was originally published in Scrip
Dr Jeffrey Tobias has joined Jazz Pharmaceuticals as chief medical officer and senior vice-president of R&D, effective October 17. Dr Tobias has 20 years' experience in the biopharma industry and most recently served as executive vice-president of R&D at NeurogesX, where he was also CMO from 2005. Jazz recently announced that it is taking over Azur Pharma (scripintelligence.com, 22 September 2011).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.